Project title | RCTs included (n) | Selection criteria | n | Citation | ||
---|---|---|---|---|---|---|
 |  |  | Total | Donepezil | Placebo |  |
Rates of cognitive change in AD: observations across a decade of placebo-controlled clinical trials with donepezil | 13 | Baseline MMSE scores between 10 and 26 Received placebo | 3403 | NA | 3403 | [2] |
Effectiveness of donepezil in reducing clinical worsening in patients with mild to moderate AD | 3 | Baseline MMSE scores between 10 and 26 Duration of at least 24 weeks Available patient-level data for cognitive, global and functional assessments | 906 | 518 | 388 | [3] |
Predicting cognitive decline in AD: an integrated analysis | 14 | Baseline and end-of-study (12- or 24-week) data on cognition, (MMSE and/or ADAS-cog) | 3748 | 2238 | 1510 | [6] |
Effect of donepezil on emergence of apathy in mild to moderate AD | 2 | MMSE scores between 10 and 26 At least 24 weeks' treatment duration Individual patient-level behavioural data using the NPI available | 490 | 241 | 249 | [7] |
Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe AD | 6 | Available post-baseline functional data collected using at least 1 ADL scale as defined in the original study protocols | 2194 | 1268 | 926 | [4] |
Effect of donepezil on cognition in severe AD: a pooled data analysis | 4 | Available SIB data at both baseline and at study end | 904 | 481 | 423 | [5] |